Differential Transcription Profiling in Bone Marrow Mononuclear Cells Between Myasthenia Gravis Patients With or Without Thymoma

Jingqun Tang

Guangxi Medical University First Affiliated Hospital

Ziming Ye

Guangxi Medical University First Affiliated Hospital

Yi Liu

Guangxi Medical University First Affiliated Hospital

Mengxiao Zhou

Guangxi Medical University First Affiliated Hospital

chao qin (✉ mdqc2019@126.com)

Guangxi Medical University First Affiliated Hospital

Research

Keywords: Myasthenia gravis, bone marrow mononuclear cells, RNA sequencing, mRNAs, thymoma

Posted Date: September 2nd, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-837123/v1>

License: This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

Abstract

Purpose

Defective stem cells have been recognized as being associated with autoimmune diseases, such as systemic lupus erythematosus, rheumatoid arthritis, autoimmune cytopenias and myasthenia gravis (MG). However, the differential gene expression profile of bone marrow mononuclear cells (BMMCs) and the molecular mechanisms underlying MG pathogenesis have not been fully elucidated. Therefore, we investigated the abnormal expression and potential roles and mechanisms of mRNAs in BMMCs among patients with MG with or without thymoma.

Methods

Transcription profiling of BMMCs in patients with MG without thymoma (M2) and patients with thymoma-associated MG (M1) was undertaken by using high-throughput RNA sequencing (RNA-Seq), and disease-related differentially expressed genes were validated by quantitative real-time polymerase chain reaction (qRT-PCR).

Results

RNA-Seq demonstrated 60 significantly upregulated and 65 significantly downregulated genes in M2 compared with M1. Five disease-related differentially expressed genes were identified and validated by qRT-PCR analysis. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed to predict the functions of aberrantly expressed genes. Recombination activating 1 (RAG1), RAG2, BCL2-like 11, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform and repressor element-1-silencing transcription factor might play roles in MG pathogenesis involving the primary immunodeficiency signaling pathway, signaling pathways regulating pluripotency of stem cells and forkhead box O signaling pathway.

Conclusion

The aberrantly expressed genes of BMMCs in M1 or M2 patients demonstrate the underlying mechanisms governing the pathogenesis of MG.

Highlights

Defective stem cells have been recognized associated with myasthenia gravis.

Some differential expression genes were found in patients with MG without thymoma compared to patients with thymoma-associated MG using high-throughput RNA sequencing.

RAG1, RAG2, BCL2L11, PIK3CA and REST might play potential roles in the pathogenesis of MG.

1. Introduction

Myasthenia gravis (MG) is a neuromuscular disorder characterized by muscle weakness and easy fatigability upon exertion. MG is mediated by autoantibodies against postsynaptic structural proteins of neuromuscular junctions: most antibodies target acetylcholine receptor (AChR), the less frequent muscle-specific kinase (MuSK) or low-density lipoprotein receptor-related protein 4 (LPR4) ^[1]. Up to 60% to 80% of patients with MG have thymic hyperplasia and 21% have thymoma ^[2, 3]. To the best of our knowledge, the thymus plays an initial role in triggering humoral immunity in MG because of either thymic hyperplasia or thymoma of lymphoproliferative origin ^[4-7]. However, the exact mechanisms leading to autoimmunity dysfunction and chronicity in patients with MG have not been elucidated. Despite improvements in treatment due to multiple therapies, including thymectomy, approximately 10% of patients with MG are considered treatment-refractory ^[8], highlighting the need for further understanding of the pathophysiology and identification of organism biomarkers to characterize the pathogenesis of the disease and to monitor the therapeutic response.

Immune dysregulation may originate from defects in the proliferation and differentiation of bone marrow (BM)-derived hematopoietic stem cells (HSCs) and/or hematopoietic support function of BM stromal cells, indicating that autoimmune diseases may primarily result from stem cell dysfunction^[9-11]. Porta et al.^[12] and Papadaki et al.^[13] compared the proliferation and differentiation of HSCs and hematopoietic support function of BM stromal cells between patients with rheumatoid arthritis (RA) and healthy controls; their results showed that the numbers of CD34⁺ BM cells, the proliferating capacity of BM myeloid precursors and the percentage of erythroid burst-forming units and colony-forming unit assays of granulocyte macrophage colonies significantly decreased, and the hematopoietic support function of BM stromal cells was abnormal in RA patients. Furthermore, patients with autoimmune cytopenias secondary to systemic autoimmune disease exhibited increased apoptosis of BM progenitor cells, leading to low CD34⁺ cell numbers and abnormal hematopoietic supporting capacity of BM stromal cells due to aberrant, local or systemic inhibitory cytokine production or intricate interactions between hematopoietic and immune cells present within the BM microenvironment^[14].

Nevertheless, the immune system emerging from the autologous HSCs of patients with MG is complex, and the pathogenesis of autoimmune dysfunction in the disease has not been fully elucidated. Over the past decade, genome-wide association studies (GWAS) and gene expression studies have provided novel insights into MG. Recently, gene expression profiles from specific cell subsets have been shown to be better determinants of immune status than whole-blood or peripheral-blood mononuclear cell (PBMC) profiles due to the diversity of leukocyte responses^[15]. In this study, we investigated to explore the core transcriptional signature and crucial pathways of BM mononuclear cells (BMMCs) from patients with thymoma-associated MG (M1) and those with MG without thymoma (M2). A global landscape of dysregulated gene signatures was first obtained using high-throughput RNA sequencing (RNA-Seq), followed by pathway analysis and subsequent immune profiling. The findings obtained in this study may help to elucidate the heterogeneity of the disease and identify biomarkers and pathways driving disease pathogenesis.

2. Materials And Methods

2.1. Study patients

The cohort study was designed in two stages and included 36 patients from the outpatient department of the Department of Neurology of the First Affiliated Hospital of Guangxi Medical University. According to whether the patients had thymoma, all patients were divided into group M1 (n = 18) and group M2 (n = 18). For the RNA-Seq stage, we selected three patients from groups M1 and M2. For the quantitative real-time reverse transcription-polymerase chain reaction (qRT-PCR) step, all patients from the two groups were compared. MG was diagnosed based on the clinical evidence of muscle weakness and fatigue and at least one positive ancillary diagnostic test, including proof of pathological decrement in repetitive nerve stimulation or a positive response to a neostigmine test. Positive detection of autoantibodies against AChR in patients further supported the diagnosis. The Myasthenia Gravis Foundation of America (MGFA)^[16] clinical classification was also employed to identify the MG subgroups. Regardless of the length of time over which the symptoms of MG appeared, all patients were coming to our clinic for the first time. All patients completed the collection of BM specimens prior to treatment with glucocorticoids, intravenous immunoglobulin, immunosuppression or thymectomy. The patients also had no clinical symptoms of metabolic disease, infectious disease nor any autoimmune diseases, including thyroid disorders, systemic lupus erythematosus (SLE), RA and Sjogren syndrome. Table 1 summarizes the demographic and baseline clinical data of the study subjects. All patients signed informed consent forms. The study was approved by the Medical Ethics Committees of the Institute of the First Affiliated Hospital of Guangxi Medical University.

2.2. Isolation of BMMCs

Using 2 mL 2% lidocaine hydrochloride (Harvest Pharmaceutical Co., Ltd, Shanghai, China) for local infiltration anesthesia, aspirate 10 mL of fresh BM from the patient's posterior iliac crest, and then immediately dilute it at a ratio of 1:1 in Iscove's modified Dulbecco's medium (IMDM; GibcoBRL, Life Technologies, USA) supplemented with 10 IU/mL preservative-free heparin (Tianjinshenghua; China) and 100 IU/mL penicillin streptomycin (Solarbio Life Science, China). The diluted samples were centrifuged with a Ficoll Hypaque gradient density (Lymphoprep; StemCell Technologies, Vancouver, BC, Canada) at a speed of 800× g for 30 mins at room temperature. BMMCs were collected from the second interphase, washed twice with the abovementioned medium and resuspended in IMDM at a concentration of 10⁷ cells/mL. Freshly sorted BMMCs were frozen in a Cryostor CS10 (StemCell Technologies, Vancouver, BC, Canada) according to the manufacturer's protocol and stored in liquid

nitrogen. The sequencing samples (n = 3 per group) were sent to Gene Denovo Biotechnology Co. (Guangzhou, China) for further processing.

2.3. Flow cytometry (FC) and immunophenotyping analyses

BMMCs (50 μ L 10^7 cells/mL) were labeled with 5 μ L PE anti-CD34 (Abcam, Cambridge, UK) and 10 μ L FITC anti-CD38 (Abcam, Cambridge, UK) fluorescent mouse monoclonal antibodies and analyzed on a FACScan FC (Becton Dickinson, San Jose, CA) according to the manufacturer's protocol. Data for a minimum of 100,000 events were acquired and processed with FlowJo software (Version 10.0; Ashland, OR).

2.4. RNA extraction and quality control

Total RNA was harvested for library construction and sequencing. In brief, total RNA was extracted from samples by using a TRIzol reagent kit (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol and subjected to an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA) and RNase free agarose gel electrophoresis for quality and purity tests, respectively. The RNA integrity number for each sample was higher than 7, indicating that the extracted RNAs possessed high quality and integrity. The ratios of optical density (OD) 260/280 in all samples were between 1.8 and 2.0, indicating high purity of extracted RNAs. The OD260/230 ratios in all samples ranged from 1.8 to 2.2, signifying an absence of organic extraction reagent contamination. The Q30 value of each sample was greater than 91%. Thus, the samples were determined to meet the quality and purity requirements for high-throughput sequencing.

2.5. mRNA-Seq Library Construction and Sequencing

After the total RNAs were extracted, ribosomal RNAs (rRNAs) were removed to retain mRNAs by using an oligo (dT) RiboZero Magnetic Gold Kit (Illumina, USA). The enriched mRNAs were fragmented and reverse-transcribed into cDNA. Next, the cDNA fragments were purified with a QiaQuick PCR extraction kit (Qiagen, Venlo, The Netherlands), end-repaired, subjected to poly (A) addition, and ligated to Illumina sequencing adapters. Next, uracil-N-glycosylase was utilized to digest second-strand cDNA. The digested products were size-selected using agarose gel electrophoresis, amplified by PCR, and sequenced using the Illumina HiSeq™ 4000 platform (Illumina, San Diego, CA, USA) by Gene Denovo Biotechnology Co. (Guangzhou, China).

2.6. Processing and mapping of mRNA-Seq reads

The Illumina HiSeq platform generated mRNA-Seq reads and removed the adaptors and low-quality reads (Q-value $\leq$ 20) bases at the 5' and 3' ends by FASTQ (version 0.18.0) [17]. The short-read alignment tool Bowtie2 (2.2.8) [18] was employed to map reads to the rRNA database. The rRNA mapped reads were subsequently removed. The remaining reads were further utilized in transcriptome assembly and analysis. The clean reads of each sample were then mapped to the reference genome by TopHat2 (version 2.1.1) [19]. The reconstruction of transcripts was performed with Cufflinks software (version 2.2.1) [20] which, together with TopHat2, enables biologists to identify new genes and new splice variants of known ones. Transcript abundances were quantified by RSEM software (version 1.2.19) [21], and the transcript expression level was normalized using the fragments per kilobase of transcript per million mapped reads (FPKM) method. Genes with expression levels > 1 FPKM were retained for further analysis.

2.7. Identification of differentially expressed mRNAs and enrichment analysis of Gene Ontology (GO) functions and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways

Scatter plots were generated, and hierarchical clustering was performed to assess and distinguish the variations in mRNA expression between the M1 and M2 groups. Aberrant mRNA expression was identified by volcano plot filtering and FC analysis. Differentially expressed gene (DEG) analysis was performed using the edgeR package (<http://www.r-project.org/>). On the basis of this method, genes with $|\log_2FC| \geq 2$ and a false discovery rate (FDR) < 0.05 were classified as DEGs between the two groups. Next, differentially expressed coding RNAs were subjected to enrichment analysis of GO functions and KEGG pathways. An FDR < 0.05 was considered to be the threshold for significant enrichment.

2.8. Verification of mRNA-Seq results for mRNA expression by quantitative real time polymerase chain reaction (qRT-PCR) analysis

Total RNA was extracted from 36 samples using a TRIzol reagent kit (Invitrogen, Carlsbad, CA, USA) as described above. RNA integrity was evaluated by 1% agarose gel electrophoresis, whereas a NanoDrop 2000 (Thermo Fisher Scientific, Inc., Waltham, MA, USA) was utilized to measure the RNA concentration and quality. Next, the samples with an OD 260/280 ratio from 1.8 to 2.0 and an OD 260/230 ratio from 1.8 to 2.2 were selected for qRT-PCR analysis. For cDNA synthesis, 1 µg of total RNA was reverse transcribed into DNA with PrimeScript™ RT Master Mix (Takara, Germany). qRT-PCR was performed at a final volume of 20 µL containing 7 µL nuclease-free water, 10 µL 2× SYBR Green I Master Mix (Roche, Basel, Switzerland), 0.6 µL PCR forward primer (10 µM), 0.6 µL PCR reverse primer (10 µM) and 2 µL RNA template. All qRT-PCR assays were performed in a StepOnePlus Real-Time PCR System (Applied Biosystems, USA) according to the following conditions: 10 min at 95 °C followed by 40 cycles of amplification (10 s at 95 °C and 30 s at 60 °C). Thirty independent biological replicates and three technical replicates of each biological replicate were obtained for qRT-PCR analysis. Table 2 shows the primers used for qRT-PCR analysis. The human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene was employed as the reference gene for data normalization. The comparative threshold cycle ($2^{-\Delta\Delta C_t}$) method of relative quantitation was employed to analyze the expression differences. C_t denotes the amplification cycles when the real-time fluorescence intensity of the reaction reached the set threshold, and when amplification was in logarithmic growth.

2.9. Statistical analysis

Data are presented as the mean ± standard deviation (SD) of the mean. The normal distribution of variables was investigated prior to statistical analysis using visual (histograms) and analytical methods (Kolmogorov–Smirnov/Shapiro–Wilk’s test). Data were recorded and analyzed with GraphPad Prism 8.0 (GraphPad Software, La Jolla, CA, USA) and IBM SPSS Statistics version 24.0 (IBM Corporation, New York, USA). Differences in mRNA levels between groups were evaluated with one-way analysis of variance (ANOVA) and Pearson’s chi-square test for categorical variables. *P*-values < 0.05 were considered to be significant.

3. Results

3.1 Subject characteristics

Table 3 presents the demographic and clinical characteristics of the M1 (*n* = 18) and M2 (*n* = 18) groups. The mean ages of the two groups were 43.82 ± 8.27 and 43.67 ± 5.89 years (*P* > 0.05). No significant differences in sex, disease duration, MGFA classification, positive AChR-Ab or previous treatment were observed between groups M1 and M2 (*P* > 0.05).

3.2 FC analysis of CD34⁺ cells

Fig. 1 shows the data from the FC analysis of CD34⁺ cells in BMMCs. The mean (± SD) proportion of CD34⁺ cells among BMMCs was significantly lower in M2 than in M1 (*n* = 18 for each group) ($1.85 \pm 0.79\%$ vs. $0.57 \pm 0.26\%$, respectively; *P* < 0.05). This reduction reflected the decreased number of committed CD34⁺CD38⁺ cells ($1.03 \pm 0.57\%$ vs. $0.31 \pm 0.17\%$, *P* ≤ 0.001) and the number of primitive CD34⁺CD38[−] cells ($0.82 \pm 0.45\%$ vs. $0.25 \pm 0.20\%$, *P* < 0.05).

3.3. DEGs

Six qualified libraries from groups M1 and M2 were sequenced. Figs. 2A and B present an overview of the mRNA sequencing data, showing 1876 DEGs with 960 upregulated and 916 downregulated mRNAs. Using the threshold values $\log_2 FC > 1$ or $\log_2 FC < -1$ and *FDR* < 0.05, we identified 125 differentially expressed mRNAs comprising 60 upregulated and 65 downregulated mRNAs (Fig. 2C), which were all annotated (Table 4) to primary immunodeficiency, forkhead box O (FOXO) signaling pathway, neurodegenerative diseases and signaling pathways regulating pluripotency of stem cells. Hierarchical clustering analysis demonstrated differentially expressed mRNAs in groups M1 and M2 (Fig. 3).

3.4. Functional annotation of differentially expressed mRNAs

GO function contains three terms: cellular component (CC), molecular function (MF) and biological process (BP). Figs. 4 and 5 show the GO analysis of upregulated and downregulated DEGs, respectively. In the CC ontology, cell (GO: 0005623), cell part (GO: 0044464), organelle (GO: 0043226), and intracellular (GO: 0005662) were significantly enriched GO terms for upregulated (Fig. 4B) and downregulated genes (Fig. 5B). In the MF ontology, the most common GO terms for significantly upregulated (Fig. 4C)

and significantly downregulated significant DEGs (Fig. 5C) were binding (GO: 0005488), ion binding (GO: 0043167) and metal ion binding (GO: 0046872). In the BP ontology, the upregulated genes (Fig. 4D) were primarily enriched in CC organization (GO: 0016043), cellular component organization or biogenesis (GO: 0071840), anatomical structure development (GO: 0048856) and developmental process (GO: 0032502). Meanwhile, the downregulated genes (Fig. 5D) were primarily enriched in the regulation of BP (GO: 0050789), biological regulation (GO: 0065007), regulation of metabolic process (GO: 0019222), regulation of macromolecular metabolic process (GO: 0060255), regulation of cellular metabolic process (GO: 0031323) and positive regulation of BP (GO: 0048518). KEGG pathway enrichment analysis indicated that the differentially expressed mRNAs were most significantly enriched in terms of signal transduction, immune system and cancer (Fig. 6).

3.5. Verification of DEGs

Five disease-related DEGs involving the primary immunodeficiency signaling pathway, signaling pathways regulating the pluripotency of stem cells and the FOXO signaling pathway were selected. These DEGs included four upregulated genes, namely, repressor element-1-silencing transcription factor (REST, also known neuron-restrictive silencer factor), BCL2-like 11 (BCL2L11, also known as BCL2 interacting mediator of cell death), recombination activating 1 (RAG1) and RAG2. One downregulated gene, phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA), was selected for further validation by qRT-PCR analysis (Fig. 7). Data regarding the expression of genes were consistent with the results obtained through RNA-Seq.

4. Discussion

MG is a chronic autoimmune disorder with a high recurrence rate, and some cases can be refractory or life-threatening. Therefore, studying the genetic mechanism governing MG is important. Researchers have previously investigated the relationship between altered expression of mRNAs and the pathogenesis of MG. To investigate a wide range of genes in BMMCs to dissect the physiological, metabolic and cellular processes of MG, we first analyzed the transcriptomic changes in BMMCs from thymoma-associated MG and MG without thymoma by conducting high-throughput sequencing and qRT-PCR analysis. RNA-Seq analysis showed that a significant number of mRNAs are altered in MG, indicating that they may play regulatory role in the pathophysiological processes of this disease.

In the present study, transcripts of 67,787 genes, of which 960 DEGs were upregulated, and 916 DEGs were downregulated, were detected using an Illumina HiSeq™ 4000 platform according to the criteria of $\log_2 FC \geq 2$ and P -values < 0.05 with the edgeR package (<http://www.r-project.org/>). The aberrantly expressed mRNAs contained a certain proportion of previously undescribed mRNAs. This result indicates that the current mRNA database is incomplete and needs to be further supplemented. Among these mRNAs, five disease-related DEGs involved in primary immunodeficiency, signaling pathways regulating the pluripotency of stem cells and the FOXO signaling pathway were selected for further validation by qRT-PCR. The results demonstrated that RAG1, RAG2, BCL2L11 and REST were significantly upregulated, whereas PIK3CA was significantly downregulated in MG samples without thymoma compared with thymoma-associated MG samples. Our findings showed consistency in qRT-PCR and RNA-Seq data. Notably, the FOXO signaling pathway involving the upstream gene PIK3CA and the downstream genes RAG1, RAG2, BCL2L11 and REST may be important to MG pathogenesis.

Precise annotation of mRNA functions remains complex. In this study, we interpreted the mRNA functions based on coexpression gene GO and KEGG pathway analyses by using pathway-related database^[22] and GO databases (<http://www.geneontology.org/>). As shown in Table 4, RAG1 and RAG2 were associated with primary immunodeficiency and the PI3K–FOXO signaling pathway involving BPs, MFs and CCs. Recent studies^[23] have highlighted the key role played by FOXO1, which has emerged as a critical target of the PI3K–FOXO pathway in the preservation of the HSC pool, regulation of progenitor commitment, and development and differentiation of B-cells by regulating its critical target genes, which include PIK3CA, early B-cell factor, RAG1, interleukin-7 receptor, activation-induced cytidine deaminase and L-selectin. RAG1 and RAG2 play important roles in the development and function of T and B cells and the immune system. In addition, the dysfunctions and hypomorphic mutations associated with these genes may result in malignancies of the hematopoietic system, primary immunodeficiency diseases and severe combined immunodeficiency (SCID), Omenn syndrome (OS) and autoimmunity^[24–27]. Brauer et al.^[28] investigated T-cell development and T-cell receptor (TCR) V(D)J recombination by using differentiation of human-induced pluripotent stem cells generated from patients (SCID versus OS) with different RAG1 mutations in vitro; these researches detected no TCR- α/δ excision circle (a marker of TCR- α/δ locus

rearrangements) in SCID- and OS-derived T-lineage cells, which was consistent with a pre-TCR block in T-cell development; this result elucidates important differences that explain the wide range of immunological phenotypes resulting from different mutations within the same RAG1 of various patients. In our study, PIK3CA and RAG1/RAG2 were significantly downregulated and upregulated in M2 patients, respectively. This finding suggests that the PI3K (PIK3CA)-FOXO-RAG1/RAG2 signaling pathway may play a key role in the occurrence and development of MG. Meanwhile, opposite expression levels of PIK3CA and RAG1/RAG2 were observed in M1 patients in relation to their dysfunction or mutation, necessitating further functional verification and mechanistic research.

Apoptosis plays an essential role in the development, function and homeostasis of the immune system. Experiments with transgenic and gene knockout models have shown that BCL2L11 is a critical regulator of the negative selection of B lymphocytes in BM HSCs and T lymphocytes in the thymus and periphery [29-31]. The phenotype of BCL2L11-deficient mice is an SLE-like autoimmune disease with an abnormal accumulation of self-reactive lymphocytes and HSCs and autoantibody production [32, 33]. Furthermore, BCL2L11 knockout mice fail to delete autoreactive T cells in the thymus, which leads to enhanced self-reactive T effector cell function followed by exacerbation of kidney disease [31]. In our work, the BCL2L11 gene was significantly downregulated in M1 patients relative to M2 patients. In addition, the percentage of HSCs significantly increased in M1 patients compared with M2 patients. This result suggests that BCL2L11 may be an important regulator of homeostasis of the BM hematopoietic system, as described above. However, the correlation or coordinated regulation system of BCL2L11 with other apoptotic molecules has not been elucidated. Further studies are warranted to determine the coordinated aspects of the effect of BCL2L11 on the immune system.

REST is a zinc finger transcription factor that plays negatively regulated roles in neuronal stem and progenitor cell (NSPC) development and differentiation by recruiting transcriptional and epigenetic regulatory cofactors to repressor element-1 in the promoter regions of neuronal genes [34, 35]. Recent studies [36] showed that in the T cell/neuron coculture model, activated CD4⁺ T cells reduced the activity of neurons and [extracellular signal-regulated kinase 1/2](#), causing REST mRNA upregulation and thereby mediating the downregulation of REST-mediated neuronal cell adhesion molecule L1, which exhibited an unexpected functions in the pathological crosstalk between the immune and nervous systems. Bergsland et al. [37] noted that blocking the function of REST led to loss of alterations in chromatin modifications and the suppression of nitric oxide-induced neuronal to glial switching. This result indicates that REST is an important factor in the NSPC-specific response to innate immunity. In our study, using RNA-Seq technology and qRT-PCR analysis, we determined that REST was upregulated in M2 patients, with the most enriched GO terms including 'negative regulation of nervous system development', 'regulation of mesenchymal stem cell differentiation', 'transcription factor binding' and 'muscle structure development' in the pathogenesis between M1 and M2 patients (Fig. 4). However, these findings suggest an unknown role of REST in the control of neuronal gene transcription in response to neuroimmunity. This unknown function may be investigated in future works involving gene transfection/knockdown, possibly helping to elucidate the pathogenesis of MG. Additional studies are required to confirm the biological function of these genes.

Our research features several limitations. First, the RNA-Seq data were limited to a small number of samples. The qRT-PCR results were acquired from a small sample consisting of 18 M1 patients and 18 M2 patients. Further studies employing a large sample size are necessary to evaluate and validate the results. Most of the conclusions of this study were also generated based on RNA-Seq data analysis. Furthermore, we annotated the functions of abnormally expressed mRNAs and were unable to validate the function of disease-related DEGs, which warrants further systematic research. In the future, we aim to further investigate and focus on the functional verification and molecular mechanisms of mRNAs in the pathological process of MG.

Conclusion

A total of 1876 DEGs were identified between M1 and M2 patients. RAG1, RAG2, BCL2L11, PIK3CA and REST were suggested to play important roles in the pathogenesis of MG. Nevertheless, the lack of biological experiments was a major limitation of the present study. Further research should be designed to support our results and investigate the molecular mechanisms underlying the pathological process of MG.

Declarations

Ethics approval and consent to participate

The study was approved by the Medical Ethics Committees of the Institute of the First Affiliated Hospital of Guangxi Medical University. All patients consent to participate the study.

Consent for publication

Not applicable.

Appendix A. Supplementary data

The datasets generated for this study can be found in NCBI (BIOPROJECT accession number PRJNA660526, SRA accession number SRP279695).

Competing interests

The authors declare that they have no commercial or financial conflicts of interest.

Funding

This research was supported by the National Natural Science Foundation of China (No. 81860222 and 81960220) and the Natural Science Foundation of Guangxi, China (No. 2018 GXNSFAA185029 and 2019GXNSFDA185008).

Authors' contributions

Jingqun Tang, Ziming Ye and Yi Liu designed the study. Jingqun Tang and Mengxiao Zhou collected the clinical data. Jingqun Tang, Ziming Ye and Yi Liu analysed the data and drafted. Jingqun Tang, Ziming Ye, Yi Liu and Chao Qin revised the manuscript. Chao Qin supervised the study. All authors read and approved the final manuscript.

Acknowledgements

We thank our patients for participating in this study. We are grateful to Guangzhou Genedenovo Biotechnology Co., Ltd for assisting in sequencing and bioinformatics analysis.

References

- [1] Vincent A, Huda S, Cao M, et al. Serological and experimental studies in different forms of myasthenia gravis [J]. *Annals of the New York Academy of Sciences*, 2018, 1413(1):143-153.
- [2] Leite MI, Ströbel P, Jones M, et al. Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG [J]. *Ann Neurol*, 2005, 57(3):444-448.
- [3] Cron MA, Maillard S, Villegas J, et al. Thymus involvement in early-onset myasthenia gravis [J]. *Annals of the New York Academy of Sciences*, 2018, 1412(1):137-145.
- [4] A. Marx, F. Pfister, B. Schalke, et al. The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes [J]. *Autoimmun Rev*, 2013, 12(9):875-884.
- [5] F. Romi, Y. Hong, N. E. Gilhus. Pathophysiology and immunological profile of myasthenia gravis and its subgroups [J]. *Curr Opin Immunol*, 2017, 49(9-13).
- [6] P. Cufi, P. Soussan, F. Truffault, et al. Thymoma-associated myasthenia gravis: On the search for a pathogen signature [J]. *Journal of autoimmunity*, 2014, 52(29-35).
- [7] S. Berrih-Aknin, R. Le Panse. Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms [J]. *Journal of autoimmunity*, 2014, 52(90-100).

- [8] Mantegazza R, Antozzi C. When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies [J]. *Therapeutic advances in neurological disorders*, 2018, 11(1):1756285617749134.
- [9] S. Ikehara, M. Inaba, R. Yasumizu, et al. Autoimmune diseases as stem cell disorders [J]. *Tohoku J Exp Med*, 1994, 173(1):141-155.
- [10] T. Otsuka, S. Okamura, M. Harada, et al. Multipotent hemopoietic progenitor cells in patients with systemic lupus erythematosus [J]. *J Rheumatol*, 1988, 15(7):1085-1090.
- [11] A. J. Nauta, W. E. Fibbe. Immunomodulatory properties of mesenchymal stromal cells [J]. *Blood*, 2007, 110(10):3499-3506.
- [12] C. Porta, R. Caporali, O. Epis, et al. Impaired bone marrow hematopoietic progenitor cell function in rheumatoid arthritis patients candidate to autologous hematopoietic stem cell transplantation [J]. *Bone Marrow Transplant*, 2004, 33(7):721-728.
- [13] H. A. Papadaki, H. D. Kritikos, C. Gemetzi, et al. Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha-mediated effect [J]. *Blood*, 2002, 99(5):1610-1619.
- [14] H. A. Papadaki, J. C. Marsh, G. D. Eliopoulos. Bone marrow stem cells and stromal cells in autoimmune cytopenias [J]. *Leuk Lymphoma*, 2002, 43(4):753-760.
- [15] McKinney EF, Lee JC, Jayne DR, et al. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection [J]. *Nature*, 2015, 523(7562):612-616.
- [16] Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America [J]. *The Annals of thoracic surgery*, 2000, 70(1):327-334.
- [17] Chen S, Zhou Y, Chen Y, et al. fastp: an ultra-fast all-in-one FASTQ preprocessor [J]. *Bioinformatics (Oxford, England)*, 2018, 34(17):i884-i890.
- [18] B. Langmead, S. L. Salzberg. Fast gapped-read alignment with Bowtie 2 [J]. *Nature methods*, 2012, 9(4):357-359.
- [19] Kim D, Pertea G, Trapnell C, et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions [J]. *Genome biology*, 2013, 14(4):R36.
- [20] Trapnell C, Roberts A, Goff L, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks [J]. *Nature protocols*, 2012, 7(3):562-578.
- [21] B. Li, C. N. Dewey. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome [J]. *BMC bioinformatics*, 2011, 12(323).
- [22] Nawrocki EP, Eddy SR. Infernal 1.1: 100-fold faster RNA homology searches [J]. *Bioinformatics (Oxford, England)*, 2013, 29(22):2933-2935.
- [23] Szydłowski M, Jabłońska E, Juszczynski P. FOXO1 transcription factor: a critical effector of the PI3K-AKT axis in B-cell development [J]. *International reviews of immunology*, 2014, 33(2):146-157.
- [24] Meshaal S, El Hawary R, Elsharkawy M, et al. Mutations in Recombination Activating Gene 1 and 2 in patients with severe combined immunodeficiency disorders in Egypt [J]. *Clinical immunology (Orlando, Fla)*, 2015, 158(2):167-173.
- [25] Avila EM, Uzel G, Hsu A, et al. Highly variable clinical phenotypes of hypomorphic RAG1 mutations [J]. *Pediatrics*, 2010, 126(5):e1248-1252.
- [26] Chen K, Wu W, Mathew D, et al. Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations [J]. *The Journal of allergy and clinical immunology*, 2014, 133(3):880-882.e810.

- ## Tables

No.	Age, years (at onset)	Disease durations	Thymus character and pathology	MGFA classification	AchR- Ab (nmol/l)	Titin-Ab (positive)	Previous treatment
1*	≥50	≤1y	thymoma(B2)	Ⅲa	9.634	1.830	Pb
2*	<50	>1y, <5y	thymoma(B1)	Ⅲb	7.279	1.435	Pb
3*	≥50	≥5y	thymoma(B2)	Ⅲa	2.485	-	Pb
4	<50	>1y, <5y	thymoma(B1)	Ⅲa	0.609	-	Pb
5	≥50	>1y, <5y	thymoma(B1)	Ⅰ	8.008	-	no
6	<50	>1y, <5y	thymoma(B1)	Ⅲa	—	-	Pb
7	<50	≥5y	thymoma(B2)	Ⅲa	8.435	-	no
8	<50	>1y, <5y	thymoma(B2)	Ⅲb	6.813	-	no
9	<50	≤1y	thymoma(B1)	Ⅲb	1.029	-	Pb
10	<50	>1y, <5y	thymoma(B2)	Ⅲa	0.621	-	Pb
11	<50	>1y, <5y	thymoma(B2)	Ⅲa	10.097	-	Pb
12	<50	≤1y	thymoma(B1)	Ⅰ	—	-	no
13	≥50	>1y, <5y	thymoma(B2)	Ⅲb	8.622	-	Pb
14	≥50	>1y, <5y	thymoma(B2)	Ⅲb	16.976	2.021	Pb
15	<50	>1y, <5y	thymoma(B1)	Ⅰ	17.698	-	Pb
16	<50	>1y, <5y	thymoma(B2)	Ⅲa	2.714	-	Pb
17	≥50	≥5y	thymoma(B2)	Ⅲb	13.79	-	no
18	<50	>1y, <5y	thymoma(B1)	Ⅲa	20.743	-	Pb
19*	<50	≥5y	normal	Ⅰ	12.059	-	Pb
20*	≥50	>1y, <5y	normal	Ⅲa	7.656	-	Pb
21*	<50	≤1y	normal	Ⅲa	—	-	Pb
22	<50	≥5y	normal	Ⅰ	0.655	-	no
23	<50	>1y, <5y	normal	Ⅲb	17.533	-	no
24	<50	>1y, <5y	normal	Ⅲa	1.458	-	Pb
25	<50	≥5y	normal	Ⅲa	—	-	no
26	<50	≤1y	normal	Ⅰ	1.007	-	Pb
27	<50	>1y, <5y	normal	Ⅲa	9.78	-	Pb
28	<50	>1y, <5y	normal	Ⅲb	15.254	-	Pb
29	<50	>1y, <5y	normal	Ⅲa	12.58	-	Pb
30	<50	>1y, <5y	normal	Ⅲb	6.56	-	no
31	<50	≤1y	normal	Ⅰ	13.215	-	no
32	<50	>1y, <5y	normal	Ⅲb	—	-	Pb
33	<50	>1y, <5y	normal	Ⅲb	15.254	-	Pb
34	≥50	≤1y	normal	Ⅲb	4.384	-	no

35	<50	>1y, <5y	normal	□	–	-	no
36	<50	>1y, <5y	normal	■a	1.396	-	Pb

F: Female; M: Male; *: for RNA-seq; *MGFA*: Myasthenia gravis foundation of America; *AchR-Ab*: Autoantibodies against acetylcholine receptors; –: Negative autoantibodies, including AchRs-Ab, MuSK-Ab, and LPR4-Ab; -: Negative Titin-Ab; *Pb*: Pyridostigmine bromide

Table 2 Gene specific primers used for qRT-PCR

Gene	Primer sequences (5'-3')
RAG1	F- GAGCAAGGTACCTCAGCCAGCAT
	R- GGATCTCACCCGGAACAGCTT
RAG2	F- ACCTCCCTCCTCTTCGCTAC
	R- AGAAGGCATGTATGAGCGTCC
REST	F- AGCTGGGGATAATGAGCGAGT
	R- ACATTTATATGGGCGTTCTCCTGT
BCL2L11	F- GCCCTTGTTCCCCCAAATGT
	R- ACCTTCTCGGTCACACTCAGA
PIK3CA	F- AGAGCCCCGAGCGTTTCT
	R- TTCACCTGATGATGGTCGTGG
GAPDH	F- CTCGCTTCGGCAGCACA
	R- AACGCTTCACGAATTTGCGT

F: forward, R: reverse

Table 3 Demographic and clinical features of the patients

	thymoma-associated MG (M1, n=18)	MG without thymoma (M2, n=18)	P value
Mean age (years)	43.82 ± 8.27	43.67 ± 5.89	0.949
Gender (Female/Male)	12/6	11/7	1.000
Disease durations (≤1y/>1y, <5y/≥5y)	3/12/3	4/11/3	0.911
MGFA classification(□/■a/□b/■a/□b/■b)	3/1/2/5/3/3/1	5/2/4/2/2/3/0	0.679
Positive AchR-Ab	16/18(88.9%)	14/18(77.8%)	0.658
Previous treatment	13/18(72.2%)	11/18(61.1%)	0.725

MG: myasthenia gravis; *MGFA*: Myasthenia gravis foundation of America; *AchR-Ab*: Autoantibodies against acetylcholine receptors

Table 4 60 upregulated and 65 downregulated differentially expressed genes are annotated

Gene ID	M1 (FPKM)	M2 (FPKM)	log2 (FC)	P value	Gene symbol	Regulation	Annotation
gene_250784	0.001	21.11	14.36564	3.41E-07	RPS4Y1	Up	ribosomal protein S4 Y-linked 1
gene_268059	0.001	2.186667	11.09452	5.92E-05	PML	Up	promyelocytic leukemia
gene_270861	0.001	1.27	10.31061	7.52E-06	PLK4	Up	polo like kinase 4
gene_282701	0.013333	1.063333	6.317413	2.60E-05	BMP3	Up	bone morphogenetic protein 3
gene_299440	0.21	5.816667	4.791731	1.20E-11	RAG1	Up	recombination activating 1
gene_0309042	0.006667	4.3	9.333155	8.95E-07	REST	Up	RE1 silencing transcription factor
gene_311469	0.001	5.603333	12.45207	3.30E-05	COQ2	Up	coenzyme Q2, polyprenyltransferase
gene_311485	0.023333	4.423333	7.566598	9.83E-08	RAG2	Up	recombination activating 2
gene_317961	0.001	19.27333	14.23432	1.58E-08	KDM5D	Up	lysine demethylase 5D
gene_329134	0.001	6.766667	12.72423	2.69E-07	UTY	Up	ubiquitously transcribed tetratricopeptide repeat containing, Y-linked
gene_336079	0.003333	19.39333	12.50631	7.12E-08	DDX3Y	Up	DEAD-box helicase 3 Y-linked
gene_338981	0.001	5.49	12.42259	5.14E-08	USP9Y	Up	ubiquitin specific peptidase 9 Y-linked
gene_356427	0.001	1.34	10.38802	6.73E-06	ATF7IP2	Up	activating transcription factor 7 interacting protein 2
gene_359649	0.001	2.38	11.21675	9.71E-06	OSCAR	Up	osteoclast associated, immunoglobulin-like receptor
gene_360726	0.001	1.633333	10.6736	7.13E-05	PAQR8	Up	progesterone and adipoQ receptor family member 8
gene_361059	0.001	1.136667	10.15059	5.46E-06	MATR3	Up	matrin 3
gene_361365	0.001	7.926667	12.9525	1.59E-05	EIF1AY	Up	eukaryotic translation initiation factor 1A Y-linked
gene_362096	0.001	5.686667	12.47337	3.04E-07	UTY	Up	ubiquitously transcribed tetratricopeptide repeat containing, Y-linked
gene_368873	0.001	3.213333	11.64985	2.01E-09	PI4KB	Up	phosphatidylinositol 4-kinase beta
gene_371174	1.49	17.24667	3.532933	6.95E-08	DNTT	Up	DNA nucleotidylexotransferase
gene_372189	0.001	2.326667	11.18405	1.02E-05	RAPGEF1	Up	Rap guanine nucleotide exchange factor 1
gene_382896	0.001	1.306667	10.35168	5.28E-	UTY	Up	ubiquitously transcribed

				05			tetratricopeptide repeat containing, Y-linked
gene_383052	0.001	1.793333	10.80843	3.75E-05	ZFY	Up	zinc finger protein Y-linked
gene_415496	0.001	1.23	10.26444	3.03E-07	MGRN1	Up	mahogunin ring finger 1
gene_420027	0.001	6.023333	12.55635	3.21E-05	UBE2V1	Up	ubiquitin conjugating enzyme E2 V1
gene_422452	0.001	0.493333	8.946419	2.78E-07	TENM1	Up	teneurin transmembrane protein 1
gene_430575	0.02	64.27667	11.65008	2.01E-07	RPS4Y1	Up	ribosomal protein S4 Y-linked 1
gene_447204	0.001	3.22	11.65284	4.06E-05	TMEM176B	Up	transmembrane protein 176B
gene_521604	0.001	8.37	13.03101	6.08E-07	TCEA1	Up	transcription elongation factor A1
gene_530853	0.001	1.256667	10.29539	5.85E-07	NIN	Up	ninein
gene_539144	0.001	2.033333	10.98963	9.41E-06	NLRC5	Up	NLR family CARD domain containing 5
gene_619294	0.001	0.986667	9.946419	5.67E-06	BCL2L11	Up	BCL2 like 11
gene_624098	0.001	2.423333	11.24278	1.30E-05	UTY	Up	ubiquitously transcribed tetratricopeptide repeat containing, Y-linked
gene_624995	0.001	7.38	12.84941	7.62E-07	SLC27A3	Up	solute carrier family 27 member 3
gene_645237	0.001	1.503333	10.55395	4.19E-05	ABCC4	Up	ATP binding cassette subfamily C member 4
gene_649336	0.01	2.75	8.103288	7.78E-05	EPG5	Up	ectopic P-granules autophagy protein 5 homolog
gene_3463	0.001	1.603333	10.64686	1.29E-05	AGL	Up	BAD92104.1 amylo-1,6-glucosidase, 4-alpha-glucanotransferase isoform 1 variant, partial
gene_5160	0.001	0.76	9.569856	1.05E-07	-	Up	XP_016805049.1 PREDICTED: SLAM family member 5-like
gene_16229	0.001	0.423333	8.72565	4.60E-05	BMS1	Up	XP_016773683.1 PREDICTED: ribosome biogenesis protein BMS1 homolog
gene_16521	0.001	0.293333	8.196397	1.27E-05	TET1	Up	NP_085128.2 methylcytosine dioxygenase TET1
gene_25497	0.001	0.806667	9.655829	4.79E-06	NCAM1	Up	XP_018892340.1 PREDICTED: neural cell adhesion molecule 1 isoform X18
gene_27189	0.003333	5.01	10.55363	6.62E-06	EIF4G2	Up	XP_017703410.1 PREDICTED: eukaryotic translation initiation factor 4 gamma 2, partial

gene_49331	0.001	1.673333	10.70851	7.43E-05	HERC2	Up	BAA20846.2 KIAA0393 protein, partial
gene_62599	0.001	1.2	10.22882	1.65E-05	ANKRD11	Up	NP_037407.4 ankyrin repeat domain-containing protein 11
gene_70098	0.001	1.603333	10.64686	1.73E-06	ITGA2B	Up	XP_011523052.1 PREDICTED: integrin alpha-IIb isoform X2
gene_72837	0.001	0.983333	9.941537	9.00E-09	LDLRAD4	Up	NP_852146.1 low-density lipoprotein receptor class A domain-containing protein 4 isoform alpha 1
gene_74149	0.001	2.953333	11.52813	2.14E-05	ZBTB14	Up	XP_012882653.1 PREDICTED: zinc finger and BTB domain-containing protein 14
gene_74162	0.003333	2.26	9.405141	1.59E-08	Epb41l3	Up	XP_016881117.1 PREDICTED: band 4.1-like protein 3 isoform X15
gene_81082	0.001	3.586667	11.80843	3.53E-14	AP3D1	Up	NP_003929.4 AP-3 complex subunit delta-1 isoform 2
gene_81799	0.001	2.973333	11.53787	8.70E-06	TYK2	Up	NP_003322.3 non-receptor tyrosine-protein kinase TYK2
gene_87092	0.001	1.066667	10.05889	7.78E-05	PAPOLG	Up	XP_005264557.1 PREDICTED: poly(A) polymerase gamma isoform X1
gene_103068	0.001	0.966667	9.916875	8.15E-05	MX2	Up	NP_002454.1 interferon-induced GTP-binding protein Mx2
gene_105593	0.006667	2.443333	8.517669	3.43E-08	HMGXB4	Up	XP_006724165.1 PREDICTED: HMG domain-containing protein 4 isoform X3
gene_115118	0.001	0.546667	9.094518	1.68E-05	PBRM1	Up	XP_016862253.1 PREDICTED: protein polybromo-1 isoform X27
gene_136880	0.001	1.453333	10.50515	7.77E-06	Qki	Up	NP_001288014.1 protein quaking isoform 5
gene_138503	0.001	1.84	10.84549	2.19E-07	SLC26A8	Up	NP_443193.1 testis anion transporter 1 isoform a
gene_147879	0.001	3.116667	11.60579	2.37E-13	RASA4	Up	NP_001073346.2 ras GTPase-activating protein 4 isoform 2
gene_152552	0.001	0.866667	9.759333	1.18E-10	Pol	Up	XP_016814018.1 PREDICTED: tubulin beta chain-like isoform X1
gene_168120	0.001	7.723333	12.91501	2.47E-07	TXLNG	Up	BAG64458.1 unnamed protein product
gene_168126	0.003333	5.046667	10.56415	1.80E-06	TXLNG	Up	AAK13477.1 lipopolysaccharide-specific response 5-like protein
gene_357266	109.92	34.49	-1.6722	7.57E-	FKBP5	Down	FK506 binding protein 5

05							
gene_354903	27.90333	5.62	-2.3118	2.78E-06	PER1	Down	period circadian regulator 1
gene_268704	2.14	0.001	-11.0634	2.33E-07	SPG7	Down	SPG7, paraplegin matrix AAA peptidase subunit
gene_271850	13.68	0.001	-13.7398	1.97E-05	TPM3	Down	tropomyosin 3
gene_298552	0.996667	0.001	-9.96097	8.07E-05	TSC1	Down	TSC complex subunit 1
gene_307659	1.946667	0.001	-10.9268	3.77E-06	KIAA0232	Down	KIAA0232
gene_317276	63.95667	9.843333	-2.69988	3.27E-08	PER1	Down	period circadian regulator 1
gene_332549	9.613333	0.386667	-4.63587	3.70E-07	IL1R2	Down	interleukin 1 receptor type 2
gene_334204	0.726667	0.001	-9.50515	5.54E-05	KIF27	Down	kinesin family member 27
gene_335953	23.96333	4.51	-2.40963	9.21E-06	ZBTB16	Down	zinc finger and BTB domain containing 16
gene_370069	1.69	0.001	-10.7228	2.45E-07	GMEB2	Down	glucocorticoid modulatory element binding protein 2
gene_377126	38.57333	7.37	-2.38787	9.13E-08	KLF9	Down	Kruppel like factor 9
gene_381930	2.896667	0.001	-11.5002	3.13E-05	KLHL5	Down	kelch like family member 5
gene_395211	3.206667	0.001	-11.6469	2.06E-09	TMOD1	Down	tropomodulin 1
gene_395748	86.60667	3.43	-4.6582	4.67E-08	AREG	Down	amphiregulin
gene_396663	17.22667	3.386667	-2.34671	1.81E-05	ARL4A	Down	ADP ribosylation factor like GTPase 4A
gene_397488	1.023333	0.001	-9.99906	2.21E-05	BAIAP3	Down	BAI1 associated protein 3
gene_404875	1.236667	0.001	-10.2722	3.94E-05	POMT1	Down	protein O-mannosyltransferase 1
gene_404894	5.266667	0.001	-12.3627	4.42E-06	ARL4A	Down	ADP ribosylation factor like GTPase 4A
ENST00000408974	5.2	0.001	-12.3443	3.87E-12	DNM2	Down	dynamin 2
gene_434651	22.75333	1.213333	-4.22903	3.40E-06	HLA-DQB1	Down	major histocompatibility complex, class II, DQ beta 1
gene_475248	236.2833	45.65333	-2.37173	2.10E-07	RPL29	Down	ribosomal protein L29
gene_491737	2.783333	0.001	-11.4426	8.72E-06	THOC2	Down	THO complex 2
gene_517856	13.01	2.58	-2.33418	2.09E-06	ASPH	Down	aspartate beta-hydroxylase

gene_539778	4.22	0.001	-12.043	2.62E-05	CMIP	Down	c-Maf inducing protein
gene_541864	1.403333	0.006667	-7.71768	6.63E-06	SLC12A4	Down	solute carrier family 12 member 4
gene_542180	1.93	0.001	-10.9144	2.51E-06	SUPT20H	Down	SPT20 homolog, SAGA complex component
gene_542713	30.75667	4.29	-2.84185	1.86E-09	FKBP5	Down	FK506 binding protein 5
gene_545232	1.53	0.001	-10.5793	2.02E-06	UHRF1BP1L	Down	UHRF1 binding protein 1 like
gene_584202	82.44667	11.81333	-2.80305	2.32E-06	PER1	Down	period circadian regulator 1
gene_614420	1.14	0.003333	-8.41785	8.96E-05	KIAA1191	Down	KIAA1191
gene_614697	2.233333	0.001	-11.125	6.70E-05	ZBTB14	Down	zinc finger and BTB domain containing 14
gene_618172	3.9	0.001	-11.9293	3.61E-10	DDX27	Down	DEAD-box helicase 27
gene_619035	196.5667	17.25333	-3.51007	2.07E-05	TNFAIP3	Down	TNF alpha induced protein 3
gene_619700	5.096667	0.001	-12.3153	7.66E-05	GLIPR2	Down	GLI pathogenesis related 2
gene_621318	2.83	0.001	-11.4666	7.75E-05	MCM7	Down	minichromosome maintenance complex component 7
gene_646596	1.26	0.001	-10.2992	8.89E-06	SLC19A2	Down	solute carrier family 19 member 2
gene_648462	3.98	0.001	-11.9586	8.76E-07	IMPDH1	Down	inosine monophosphate dehydrogenase 1
gene_648685	5.486667	0.001	-12.4217	1.06E-06	ITGAM	Down	integrin subunit alpha M
gene_649979	2.896667	0.001	-11.5002	1.99E-05	IFIH1	Down	interferon induced with helicase C domain 1
gene_1716	1.866667	0.003333	-9.12928	8.15E-06	AGO3	Down	NP_079128.2 protein argonaute-3 isoform a
gene_7694	1.353333	0.001	-10.4023	1.59E-05	NLRP3	Down	NP_899632.1 NACHT, LRR and PYD domains-containing protein 3 isoform b
gene_24569	0.83	0.001	-9.69697	7.21E-06	RELT	Down	XP_011900306.1 PREDICTED: tumor necrosis factor receptor superfamily member 19L isoform X1
gene_29324	3.086667	0.001	-11.5918	1.79E-06	NUMA1	Down	XP_011543367.1 PREDICTED: nuclear mitotic apparatus protein 1 isoform X2 [Homo sapiens]
gene_31630	1.466667	0.001	-10.5183	2.22E-05	CLSTN3	Down	NP_055533.2 calsynenin-3 precursor
gene_53378	1.136667	0.001	-10.1506	2.36E-05	RFX7	Down	XP_005254660.2 PREDICTED: DNA-binding

							protein RFX7 isoform X1
gene_54225	1.046667	0.003333	-8.29462	1.18E-05	SIN3A	Down	XP_016782697.1 PREDICTED: paired amphipathic helix protein Sin3a isoform X1
gene_58683	1.513333	0.001	-10.5635	2.90E-06	CRISPLD2	Down	NP_113664.1 cysteine-rich secretory protein LCCL domain-containing 2 precursor
gene_59134	0.76	0.001	-9.56986	8.21E-05	IL9R	Down	XP_011755064.1 PREDICTED: interleukin-9 receptor-like
gene_64012	0.63	0.001	-9.29921	1.42E-07	SARM1	Down	XP_008008963.1 PREDICTED: sterile alpha and TIR motif-containing protein 1
gene_69199	1.213333	0.001	-10.2448	7.20E-05	SLFN14	Down	NP_001123292.1 protein SLFN14
gene_71099	5.78	0.001	-12.4969	8.82E-05	DDX5	Down	XP_010378302.1 PREDICTED: probable ATP-dependent RNA helicase DDX5 isoform X2
gene_74678	1.196667	0.001	-10.2248	5.13E-07	ZNF24	Down	NP_001295052.1 zinc finger protein 24 isoform 2
gene_79669	1.7	0.001	-10.7313	2.00E-08	PRR12	Down	BAA86519.1 KIAA1205 protein, partial
gene_88185	54.98	2.906667	-4.24147	8.11E-08	IL1R2	Down	XP_011510105.1 PREDICTED: interleukin-1 receptor type 2 isoform X3
gene_95320	0.923333	0.001	-9.85071	1.38E-06	ANAPC1	Down	NP_073153.1 anaphase-promoting complex subunit 1
gene_98429	0.573333	0.001	-9.16323	2.85E-05	ZNF714	Down	EAW50338.1 hCG1818014, partial
gene_112565	0.506667	0.001	-8.98489	4.47E-05	PIK3CA	Down	XP_010372245.1 PREDICTED: phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
gene_115971	1.576667	0.001	-10.6227	5.16E-05	CD47	Down	XP_005247965.1 PREDICTED: leukocyte surface antigen CD47 isoform X1
gene_116248	1.44	0.001	-10.4919	1.02E-05	GOLGB1	Down	XP_006713654.1 PREDICTED: golgin subfamily B member 1 isoform X11
gene_119869	39.02667	2.483333	-3.97411	6.47E-09	AREG	Down	XP_005965713.1 PREDICTED: amphiregulin-like isoform X1
gene_131101	0.283333	0.001	-8.14636	7.50E-05	-	Down	EAW49052.1 hCG2028242, partial

gene_133404	1.326667	0.001	-10.3736	5.07E-06	CD83	Down	NP_004224.1 CD83 antigen isoform a precursor
gene_138115	2.356667	0.001	-11.2025	8.91E-08	DDAH2	Down	ERE88825.1 N(G), N(G)-dimethylarginine dimethylaminohydrolase 2-like isoform 1
gene_166902	1.603333	0.001	-10.6469	2.03E-14	ZMAT1	Down	EAX02898.1 hCG2039319, partial

Figures

Figure 1

Percentage of bone marrow cells in thymoma-associated MG patients (M1) and MG patients without thymoma (M2) obtained from 2-color flow cytometry analysis. (A) The dot plot (pseudocolor) for gating in groups M1 and M2. (B) Significant reductions in the percentages of CD34+ cells, CD34+CD38+ cells and CD34+CD38- cells were detected in group M1 compared to group M2. n = 18

per group. Each sample was labeled with 5 μ L PE anti-CD34 and 10 μ L FITC anti-CD38 fluorescent mouse monoclonal antibodies. Data are given as the mean $\pm$ SD. *P < 0.05.

Figure 2

Overview of mRNA-Seq data. (A) Scatter plot showing the gene expression variation between thymoma-associated MG patients (M1) and MG patients without thymoma (M2). The red and green points indicate changes greater than and less than 2-fold for genes between the two groups. (B) Volcano plot of the differentially expressed genes (DEGs). The vertical lines correspond to 2-fold up and down, respectively, and the horizontal line indicates a P value < 0.05. The red and green points in the plots represent the significantly upregulated and downregulated differentially expressed genes, respectively. (C) Pie chart showing the number of up- and downregulated DEGs.

Figure 3

Hierarchical clustering of gene expression data based on FPKM values between thymoma-associated MG (M1) and MG without thymoma (M2) samples using heat maps. The transcriptional expression levels of each sample were evaluated with a logarithm value of 2, and hierarchical clustering analysis was performed for different samples and transcriptional expression. Deep red indicates high expression and dark blue indicates low expression.

Figure 4

GO analysis of upregulated differentially expressed genes. (A) The most significantly enriched GO terms in three ontologies, including biological process (BP), cellular component (CC), and molecular function (MF), are shown. The P values are arranged from lowest to highest along the X-axis. Details regarding the number of upregulated differentially expressed genes (DEGs) related to cellular components (B), molecular functions (C), and biological processes (D) are summarized.

Figure 6

Enriched KEGG pathways of differentially expressed genes (DEGs). The most significantly enriched pathways referred to signal transduction, immune system and cancers. Details regarding the number of DEGs related to KEGG pathways are also shown.

Figure 7

Identification and verification of differentially expressed genes (DEGs). Five disease-related DEGs were selected, and the mRNA levels were measured by qRT-PCR. RAG1, RAG2, BCL2L11 and REST were significantly upregulated and PIK3CA was significantly downregulated in MG samples without thymoma (M2) compared with thymoma-associated MG samples (M1). **P < 0.05 vs. group M1.